Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer

• Status: Completed
• Trial end date: 2005-08-01

Summary

The aim of this study is to determine if 3 monthly infusions of zoledronic acid, given over one year, improves the bone mineral density in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer

• Phase: N/A

Details

• Lead Sponsor: Wirral University Teaching Hospital NHS Trust
• Collaborator: Novartis
• Treatments: Androgens; Bicalutamide; Diphosphonates; Zoledronic Acid